United Therapeutics Announces Recent Milestones For Its Heart And Kidney Xenotransplantation Programs
Portfolio Pulse from Benzinga Newsdesk
United Therapeutics announced recent milestones for its heart and kidney xenotransplantation programs. The second UHeart recipient is recovering after a successful transplant and UThymoKidney demonstrated normal function during a 61-day study. Human xenotransplant clinical studies could begin in 2025.
September 22, 2023 | 6:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
United Therapeutics' recent advancements in its xenotransplantation programs could potentially lead to new product offerings and revenue streams in the future.
The successful progress in United Therapeutics' xenotransplantation programs indicates potential for new product development. This could lead to increased revenues and a positive impact on the company's stock price in the future.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100